pharma · Myelofibrosis · Myelodysplastic syndromes (MDS)
Geron Netherlands
Geron Netherlands B.V.
Geron Netherlands is a pharma organization headquartered in EU. Primary therapeutic focus areas include Myelofibrosis, Myelodysplastic syndromes (MDS). NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0
EU HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Programs
- 3
- Drugs
- 2
- Patents
- 0
GRN163LMYF3001
Phase 3 · small molecule · Myelofibrosis
GRN163LMYF3001 for Myelofibrosis is a Phase 3 program (small_molecule) at Geron Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Internal code GRN163LMYF3001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Geron Netherlands B.V.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Myelofibrosis
- Status
- active
- Trials
- 1